Skip to main content
. Author manuscript; available in PMC: 2013 Dec 1.
Published in final edited form as: FEMS Immunol Med Microbiol. 2012 Aug 1;66(3):273–280. doi: 10.1111/j.1574-695X.2012.01002.x

Table 1.

The PPD products currently used in human subjects

Name Manufacturer Dose References
PPD S2 (Aplisol®) JHP Pharmaceuticals, Inc, Rochester, MI, USA 5 TU (Villarino, et al., 1999)
PPD S2 (Tubersol®) Sanofi Pasteur Limited, Swiftwater, PA, USA 5 TU (Villarino, et al., 1999, Teixeira, et al., 2000, Rangel-Frausto, et al., 2001)
PPD RT23 SSI Statens Serum Institute, Copenhagen, Denmark 2 TU (Maes, et al., 2011, Teixeira, et al., 2000)
PPD RT23 Mexico Laboratorio Nacional de Salud, Secretaria de Salud, Mexico City, Mexico 2 TU (Rangel-Frausto, et al., 2001)
PPD RT23 (Evans PPD) Celltech Pharma S.A., Madrid, Spain 2 TU (Fernandez-Villar, et al., 2004)
PPD-s Nihon BCG Seizo Co., Tokyo, Japan 3 TU (Shigeto, 1990)
PPD IC-65 Cantacuzino Institute, Bucharest, Romania 2 TU (Ulea, et al. 2010)